Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hamilton

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
Urologic Oncology|January 13, 2023
Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillanceGuan Hee Tan, Dominik Deniffel, Antonio Finelli, et al.
European Radiology|May 4, 2022
Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsyDominik Deniffel, Nathan Perlis, Sangeet Ghai, et al.
ACS Applied Materials & Interfaces|June 7, 2018
Microdevice Platform for Continuous Measurement of Contractility, Beating Rate, and Beating Rhythm of Human-Induced Pluripotent Stem Cell-Cardiomyocytes inside a Controlled Incubator EnvironmentLi Wang, Wenkun Dou, Manpreet Malhi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 2, 2017
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?Rashid Khalid Sayyid, Dharmendra Dingar, Katherine Fleshner, et al.
European Urology Oncology|July 7, 2019
Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell TumoursPeter Chung, Martin E O'Malley, Michael A S Jewett, et al.
Urologic Oncology|January 26, 2021
Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?Jaime O Herrera-Caceres, Alexandra Gleave, Katherine Lajkosz, et al.
Heart Rhythm|February 10, 2020
Initially unexplained cardiac arrest in children and adolescents: A national experience from the Canadian Pediatric Heart Rhythm NetworkTaylor Cunningham, Thomas M Roston, Sonia Franciosi, et al.
The Journal of Urology|June 5, 2020
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?Dominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Scientific Reports|February 11, 2022
Safety and efficacy of a novel robotic transcranial doppler system in subarachnoid hemorrhageKevin Clare, Alan Stein, Nitesh Damodara, et al.
The Journal of Urology|September 24, 2020
Reply by AuthorsDominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Urologic Oncology|January 13, 2023
Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillanceGuan Hee Tan, Dominik Deniffel, Antonio Finelli, et al.
European Radiology|May 4, 2022
Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsyDominik Deniffel, Nathan Perlis, Sangeet Ghai, et al.
ACS Applied Materials & Interfaces|June 7, 2018
Microdevice Platform for Continuous Measurement of Contractility, Beating Rate, and Beating Rhythm of Human-Induced Pluripotent Stem Cell-Cardiomyocytes inside a Controlled Incubator EnvironmentLi Wang, Wenkun Dou, Manpreet Malhi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 2, 2017
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?Rashid Khalid Sayyid, Dharmendra Dingar, Katherine Fleshner, et al.
European Urology Oncology|July 7, 2019
Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell TumoursPeter Chung, Martin E O'Malley, Michael A S Jewett, et al.
Urologic Oncology|January 26, 2021
Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?Jaime O Herrera-Caceres, Alexandra Gleave, Katherine Lajkosz, et al.
Heart Rhythm|February 10, 2020
Initially unexplained cardiac arrest in children and adolescents: A national experience from the Canadian Pediatric Heart Rhythm NetworkTaylor Cunningham, Thomas M Roston, Sonia Franciosi, et al.
The Journal of Urology|June 5, 2020
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?Dominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Scientific Reports|February 11, 2022
Safety and efficacy of a novel robotic transcranial doppler system in subarachnoid hemorrhageKevin Clare, Alan Stein, Nitesh Damodara, et al.
The Journal of Urology|September 24, 2020
Reply by AuthorsDominik Deniffel, Emmanuel Salinas, Marc Ientilucci, et al.
Pageof 15